There are conflicting reports on the effect of serum from patients with insulin-dependent diabetes mellitus (IDDM) or normal human serum on -cell function and insulin secretion. Here, we report that the sera of newly diagnosed IDDM patients potently suppresses insulin secretion from a clonal rat pancreatic -cell line (BRIN-BD11), but do not alter cell viability. Indeed, the viability of the -cells was not significantly different between cells cultured in 10% (v/v) IDDM sera, normal human sera, or fetal calf serum after 24, 48 and 72 h. Alanine-stimulated insulin secretion from cells cultured for 24 h in (10% v/v) IDDM patient sera was reduced to 48% of that secreted from cells cultured in (10% v/v) normal human sera. After depletion of the complement components C1q and C3, the inhibition of insulin secretion induced by IDDM patient sera was significantly reversed (no significant difference was observed between cells cultured in complementdepleted IDDM patient sera and cells cultured in normal human sera or complement-depleted normal human sera).
Introduction
Insulin-dependent diabetes mellitus (IDDM) is a disease involving immune-mediated damage and destruction of the insulin-secreting -cells of the pancreatic islets of Langerhans. Diabetes susceptibility genes and environmental factors may be involved in the aetiology of the disease, which eventually results in autoimmune destruction of the pancreatic -cells. This autoimmune destruction may be mediated by an initial production of antibodies against -cell proteins such as glutamic acid decarboxylase (GAD), insulin, or IA-2 (also known as 40 kDa antigen or ICA 512, a protein tyrosine phosphatase-like molecule (Nepom 1995) ) and, ultimately, by complement, cytotoxic T-lymphocytes and macrophages. However, the component of the immune system that is ultimately responsible for the destruction of -cells in humans is unknown.
Autoantibodies of three broad categories are increased in the sera of individuals with IDDM, months to years before clinical onset of diabetes. One category of anti--cell antibody found in IDDM patients or their first-degree relatives contains anti-islet cell antibodies (ICA) (Bottazzo et al. 1974; McCuish et al. 1974 ) of a broad range, and complement-fixing ICAs (Bottazzo et al. 1980) . A second category contains anti-insulin antibodies (Palmer et al. 1983 , Wilkin & Nicholson 1984 , and the third category contains anti-glutamic acid decarboxylase (GAD) antibodies. Bottazzo et al. (1980) have reported that the complement-fixing ICAs that exist in the sera of IDDM patients were a more reliable marker of pancreatic -cell damage than were conventional ICAs. Bottazzo et al. (1980) also reported deposition of complement component C9 on some cells in pancreatic islets from a newly diagnosed patient with IDDM (Bottazzo et al. 1985) . However, it was not until recently that firm evidence emerged to support a direct role for complement in islet cell damage, demonstrating that complement-fixing ICAs in sera from IDDM patients could trigger the assembly of terminal complement complexes (TCC) on human islet cells (Radillo et al. 1996) . As the pancreatic donor in the last of these studies was non-diabetic, strong evidence was provided that complement activation was initiating -cell damage, rather than reacting to it.
There are a number of conflicting reports in the literature concerning the effects of the sera of patients with IDDM or non-diabetic sera on the insulin secretion and function of rodent or human islets or hamster-derived -cell lines. One study reported acute (60-90 min) stimulation of insulin secretion from the HIT-T15 cell line or human islets by IDDM patient sera (Wilkin et al. 1988) . In addition, release of insulin from mouse islets was stimulated by normal human sera over approximately 1 h of perfusion (Idahl et al. 1980) . However, 11 of 21 IDDM patient sera samples suppressed glucose-stimulated release of insulin from mouse islet cells (Boitard et al. 1981) , whereas glucose-stimulated secretion of insulin from mouse islets previously exposed to heat-inactivated IDDM patient sera in the presence of guinea pig complement for 20 h was reduced by more than 60% compared with islets incubated in control sera (Sensi et al. 1985) .
We report here the results from a study in which the rat-derived clonal pancreatic -cell line, BRIN-BD11, was exposed to either 10% sera from patients newly diagnosed with IDDM or 10% normal human sera for 24 h and then was tested for basal or alanine-stimulated release of insulin. The BRIN-BD11 cell line was chosen for the functional studies reported here because it is a robust clonal -cell line that remains fully viable in the presence of human sera and it reponds to glucose or amino-acid stimulation in a dose-dependent manner (McClenaghan et al. 1996a,b) . We also report the concentration of anti-GAD autoantibodies, the presence or absence of IAA and ICA in the sera of newly diagnosed patients, and the levels of complement activation in the human-serumsupplemented media to which pancreatic BRIN-BD11 cells or kidney epithelial LLC-PK1 cells were exposed.
Methods

Human sera samples for insulin secretion experiments
Samples were obtained by venepuncture from nine consenting newly diagnosed IDDM patients and nine agematched control individuals without a history of diabetes and with confirmed normal glucose tolerance. Blood samples were collected in silicone-coated evacuated blood tubes and allowed to clot for 20 min at room temperature. Samples were then centrifuged at 400 g for 10 min and the supernatant removed for storage at 70 C until required for use. Serum samples were subsequently freeze-thawed only once before use.
The IDDM patient blood samples were obtained from six men and three women, aged 18-34 years. Serum samples were obtained between 3 days and 4 months after the diagnosis and at least 11 h after the last insulin injection. All patients were in a fasted state at the time the blood sample was taken. the basal insulin concentration in the IDDM patients was 8·58
3·53 mU/l in this study (normal reference range 1·0-17·5 mU/l).
The nine age-matched controls consisted of eight men and one woman. The serum samples were obtained between 0830 and 1030 h after an overnight fast.
Autoantibody assay
Anti-GAD and IAA were assessed in serum samples by using an indirect ELISA. Recombinant human GAD and human insulin were the primary coating antigens, respectively. Soluble antigen was coated at 0·42 µg/ml in 60 mM carbonate buffer, pH 9·6, to plastic wells of a flatbottomed 96-well Nunc Maxisorp plate and incubated overnight at 4 C. Wells were subsequently washed four times with PBS-0·05% Tween 20. Doubling dilutions of pooled known anti-GAD or IAA-positive sera (100 µl) were incubated in the wells for 60 min at room temperature. The concentrations of sera anti-GAD or IAA were determined relative to an anti-GAD (MICA 3 1940 ng/ ml, Boehringer Mannheim, Dorval, Quebec, Canada) or IAA standard. Patients' samples were diluted 1 : 100 before incubation. Four washes with PBS-0·05% Tween 20 were carried out before incubation with rabbit antihuman immunoglobulin conjugated with horseradish peroxidase (Dakopatts, Copenhagen, Denmark) diluted 1 : 1000 (100 µl) for 60 min at room temperature. A further four washes with PBS-0·05% Tween 20 were carried out before development with 0·58 mg/ml o-phenylenediamine (OPD).2HCl, pH 5·2, to which 5 µl 30% H 2 O 2 was added. The reaction was stopped by adding 100 µl 2·5 M H 2 SO 4 . The optical density at 495 nm was determined using a Titertek Multiscan Plus MKII spectrophotometer.
ICA were detected by immunofluorescence. Briefly, sera were diluted in PBS pH 7·4 containing 1% BSA and screened on 4 µm frozen sections of human pancreas from a donor of blood group O. Sections were applied to poly--lysine-treated, Teflon coated, multi-well microscope slides and air dried. ICA were detected by a sheep antiserum to human immunoglobulin (Ig) conjugated with fluorescein isothiocyanate diluted in 0·5 M carbonate buffer, pH 9·0 containing 1% BSA. Standard 30-min incubation periods and washing procedures were used, and the sections were mounted in 90% glycerol with 0·5 M carbonate buffer. Reading was achieved using standard fluorescence microscopy.
Culture of BRIN-BD11 cells
Clonal insulin secreting BRIN-BD11 cells were maintained in RPMI-1640 tissue culture medium with 10% (v/v) fetal calf serum (FCS), 0·1% antibiotics (100 U/ml penicillin and 0·1 mg/ml streptomycin) and 11·1 mM -glucose, pH 7·4. The cells were maintained at 37 C in an atmosphere of 5% carbon dioxide and 95% air using a LEEC incubator. The cells were cultured in 20 ml tissue culture medium in 75 cm 2 sterile tissue-culture flasks. Cells were subsequently seeded in 24-well multiplates for culture in medium with and without supplementation with 10% human sera as described elsewhere (McCleneghan et al. 1996b ).
Determination of cell viability
Cell viability was determined by measuring internal lactate dehydrogenase (LDH) -that is, the enzyme activity associated with intact cells after 24, 48 and 72 h. To determine the viability of cells used in the insulin secretion experiments, BRIN-BD11 cells were plated at a density of 2·5 10 5 cells per well, and after 24 h, culture medium was removed and insulin concentration was determined in an aliquot of buffer after 20 min incubation. The remaining buffer was removed and 100 µl lysis buffer (20 mM EDTA, 10 mM Tris-HCl, 0·5% Triton-X 100, pH 8·0) were added to each well. Cell lysates were stored at 70 C until required for enzyme activity determination. LDH was measured by an adaption of the method described by Whitaker (1969) , in which NADH formation is coupled to p-iodonitrotetrazolium to form formazan; the increase in aborbance is then determined at 490 nm.
Evaluation of insulin secretion
Following 24 h of cell culture in the presence and absence of human sera, the medium was removed gently and replaced with 1 ml Krebs-Ringer bicarbonate buffer (115 mM NaCl, 4·7 mM KCl, 1·28 mM CaCl 2 , 1·2 mM KH 2 PO 4 , 1·2 mM MgSO 4 .7H 2 O, 10 mM NaHCO 3 , 5 g/l BSA, pH 7·4) containing 1·1 mM -glucose. After a 40-min preincubation at 37 C, buffer was removed and the cell monolayers were incubated in the same buffer containing either 1·1 mM -glucose or 1·1 mM -glucose supplemented with 10 mM -alanine. After 20 min incubation at 37 C, an aliquot (900 µl) of buffer was removed from each well and centrifuged at 500 g for 5 min at 4 C. The supernatant was stored at 20 C for subsequent measurement of insulin by radioimmunoassay as described elsewhere (McCleneghan et al. 1996b) . Cell density and insulin content were not significantly different for any of the incubation conditions. Triplicate wells containing equal numbers of BD11 cells were used in the assessment of the effect of each patient's serum on basal and alanine-stimulated insulin secretion.
Removal of complement components C1q and C3 from serum
Anti-C1q or anti-C3 antibodies (Sigma Chemical Company, Poole, Dorset, UK) were diluted in 10 mM phosphate buffer containing 145 mM NaCl, pH 7·2 (44 mg/ml anti-human C1q or 38 mg/ml anti-human C3). One hundred microlitres diluted anti-C1q antibodies were added to columns 1-6 of a 96-well microtitre plate, and 100 µl diluted anti-C3 were added to columns 7-12. After incubation at 4 C overnight, the buffer was removed and the wells washed three times with 10 mM phosphate buffer containing 500 mM NaCl, 0·1% w/v Tween 20 (pH 7·2). Then 100 µl sera were added to column 1 and the plate was incubated at room temperature for 40 min; after this time, the sera samples were removed and transferred to column 2, where they were incubated for 40 min and then transferred to column 3, and so on. By the time the sera samples reached column 12, they were complement-depleted (C1q and C3), as assessed by cell viability studies.
Control plates were set up with 0·1% BSA replacing anti-C1q and anti-C3. The sera obtained from the control plates had complement activation profiles similar to those of sera not added to control plates.
Determination of TCC formation in culture medium from clonal -cells exposed to various sera
Clonal insulin-secreting cells plated at a density of 1 10 6 per ml were cultured with 10% (v/v) human serum (from IDDM patients (n= 10) or normal individuals (n=11)) or 10% FCS for periods of up to 24 h. Production of TCC (SC5b-9) was determined using an enzyme immunoassay kit (Quidel, San Diego, CA, USA) as follows. The microassay wells coated with a mouse monoclonal antibody specific for human SC5b-9 were rehydrated by incubation with 250 µl wash solution (PBS, pH 7·4, containing 0·05% Tween 20 and 0·01% thiomersol) for 2 min at room temperature (20-26 C). After incubation, the wash buffer was removed and the wells blotted dry on absorbent paper. One hundred microlitre aliquots of standards (human serum containing known amounts of SC5b-9) or appropriately diluted samples were added, followed by incubation at room temperature for 1 h . After this incubation, the wells were washed five times with wash buffer and blotted dry as before. Fifty microlitres SC5b-9 conjugate (horseradish peroxidase-conjugated goat antibodies to antigens of SC5b-9 diluted in PBS, protein stabilizers, 0·01% thiomersol) were added, followed by incubation for 1 h at room temperature. After this period, the mixture was decanted and the wells washed four or five times as before. Immediately after the wash procedure, 100 µl substrate solution (0·7% 2-2 -azino-di-(3-ethylbenzthiazoline sulphonic acid) diammonium salt 50 µl/ml 0·1 M citrate buffer containing 0·05% H 2 O 2 ) was added to each well. After 30 min incubation at room temperature, the reaction was terminated by the addition of 50 µl 250 nM oxalic acid to each well. The absorbance was determined at 405 nm within 1 h.
Informed consent and ethics committee approval
All patients and controls gave informed consent to inclusion in the study. Ethical approval was obtained from the Research and Ethics Committees in participating hospitals.
Statistics
The results are presented as means .. unless stated otherwise. Groups of data were compared using unpaired or paired Student's t-test or the Mann-Whitney U-test where appropriate. Differences were considered to be statistically significant at P<0·05.
Results
Cell viability
BRIN-BD11 cell viability, determined by measurement of internal LDH activity (Table 1) , trypan blue exclusion or changes in cell morphology as assessed by electron microscopy, was not significantly different for cells cultured in 10% (v/v) FCS, IDDM patient or normal human serum after 24 h. If the culture period was extended so that cell density increased, cell viability was still not significantly different between cells cultured in FCS, IDDM patient or normal human serum after 48 h or 72 h of culture (results not shown).
Effect of exposure to newly diagnosed IDDM patient sera or C1q+C3-depleted IDDM sera on basal and alanine-stimulated insulin secretion
The rate of secretion of insulin from clonal -cells precultured in medium supplemented with 10% FCS for 24 h was 1·78 0·36 ng/20 min per 10 6 cells in the presence of 1·1 mM glucose and 13·64
1·08 ng/20 min per 10 6 cells in the presence of 1·1 mM glucose and 10 mM alanine (a stimulation ratio of 7·7). In a previous study, it was demonstrated that the alanine-induced rate of secretion of insulin from BRIN-BD11 cells was substantially greater than that induced by all other amino acids tested, glucose or -aminoisobutyric acid (McClenagan et al. 1996b) . Alanine induces insulin secretion in -cells via its oxidative metabolism, as does glucose. We determined that, after a preincubation period of 24 h in all sera types, insulin secretion was maximally stimulated by alanine (results not shown). Clonal -cells were cultured for 24 h in medium supplemented with 10% sera from nine patients newly diagnosed with IDDM or 10% C1q+C3-depleted IDDM sera from the same individuals. Complement components C1q and C3 were depleted from sera by immunoadsorption as described in the Methods section. There was a small, but statistically significant, difference (P<0·01) in basal insulin secretion from cells cultured in IDDM patient sera or complement-depleted sera (1·311 0·118 compared with 2·151 0·211 ng/20 min per 10 6 cells, n=9). However, alanine-stimulated insulin secretion was consistently greater from clonal -cells exposed to complementdepleted IDDM sera than from cells precultured in untreated IDDM sera (significantly greater from cells cultured in seven of nine sera from newly diagnosed patients; Fig. 1a ). Alanine-stimulated secretion of insulin from cells exposed to complement-depleted IDDM sera was similar to that from cells exposed to heat-treated IDDM sera (results not shown).
Effect of exposure to normal human sera or C1q+C3-depleted normal human sera on basal and alanine-stimulated insulin secretion
Clonal -cells were cultured for 24 h in medium supplemented with 10% whole or C1q+C3-depleted sera from nine normal, age-matched healthy individuals. There was no significant difference (P=0·237) in basal release of insulin release from cells cultured in normal sera or complement-depleted normal human sera (1·723 0·140 compared with 1·490 0·127 ng/20 min per 10 6 cells, n=9). The magnitude of alanine-stimulated secretion of insulin from cells cultured in normal human sera was significantly greater than that from cells cultured in IDDM sera (7·894 0·395 compared with 3·809 0·452 ng/ 20 min per 10 6 cells, repectively, n=9; P<0·001). Alanine-stimulated insulin secretion from clonal -cells precultured in complement-depleted normal human sera was slightly, but not significantly, increased compared with that from untreated normal human sera (8·537 0·930 and 7·894 0·395 ng/20 min per 10 6 cells, n=9; P=0·538) (Fig. 1b) .
Anti-GAD, anti-ICA and IAA concentrations in IDDM patient sera
The presence of antibodies to GAD is an indication of an autoimmune process that, in the majority of cases, leads to IDDM. A positive test result with an increased anti-GAD antibody concentration indicates manifest IDDM or an autoimmune process that is likely to lead to IDDM.
The anti-GAD concentration in six of the nine IDDM patient sera assessed was significantly increased compared with that from normal human controls (Fig. 2, P<0·001 in six cases). In addition, the presence or absence of ICA and IAA was assessed by comparing the results against positive standards in the appropriate assay for both autoantibodies. The autoantibody status for each of nine patient sera samples are reported in Table 2 .
Three of the nine patients were negative for all three autoantibodies. However, we did not assess the concentration of other major autoantibodies, such as protein tyrosine phosphatase IA-2 antibodies, in this study.
SC5b-9 production in culture media of clonal -cells exposed to IDDM patient sera or normal human sera
The concentrations of the serum soluble TCC (SC5b-9) during culture of clonal -cells in media supplemented with 10% IDDM sera or normal human sera are shown in Fig. 3 . We have previously shown that the concentration of SC5b-9 increased time-dependently in media supplemented with IDDM sera or normal human sera after exposure to rat pancreatic islets (Caraher et al. 1999) . Although culture medium supplemented with sera from some individual patients demonstrated substantially greater concentrations of SC5b-9 compared with the mean concentration in medium supplemented with normal human sera, overall, no statistically significant difference was found between media supplemented with IDDM patient sera or normal human serum (Mann-Whitney U-test). SC5b-9 concentrations measured in culture medium of an unrelated pig kidney epithelial cell line (LLC PK 1 ) supplemented with 10% IDDM sera were 1·007 0·095 µg/ ml after 24 h, which was actually less than the SC5b-9 concentration detected in medium supplemented with 10% normal human sera (1·572 0·197 µg/ml) cultured at the same density as BRIN-BD11 cells, indicating that complement activation in serum-supplemented culture medium was cell-specific.
Discussion
It has been suggested that complement-fixing ICAs have a role in maintaining early and continued alteration of pancreatic -cell function in prediabetes (Sensi et al. 1985) Their presence, and other coexisting phenomena such as locally increased cytokine concentrations and cellmediated autoimmune cytotoxicity, are believed to contribute to the cumulative process of -cell destruction that precipitates clinical IDDM. In a previous study, Wilkin et al. (1988) used an animal-derived -cell line (HIT-T15) and demonstrated that insulin secretion was stimulated by incubation of cells for 1 h with 33% (v/v) sera (four of Figure 2 Anti-GAD concentrations in serum from newly diagnosed patients with IDDM and from normal human individuals. Anti-GAD autoantibodies were quantified in IDDM patient sera and normal human sera samples by indirect ELISA using recombinant human GAD as primary coating antigen, as described in Methods. Values were obtained from nine newly diagnosed IDDM patients and nine healthy normal individuals. Two of the patients had similar anti-GAD values, which are superimposed in the Figure. Table 2 Autoantibody positivity in nine patients with newly diagnosed type-1 diabetes mellitus. As described in Methods, anti-GAD and IAA were quantified by indirect ELISA using recombinant human GAD and insulin, respectively, as the primary coating antigens; ICA were detected by immunofluorescence SC5b-9 concentrations in culture medium from clonal -cells exposed to IDDM and normal sera. SC5b-9 production in BRIN-BD11 cell culture medium supplemented with 10% (v/v) IDDM serum (n=11) or normal human serum (n=10) after 24 h was determined by ELISA as described in Methods.
five type-1 diabetic sera promoted stimulation of insulin secretion, compared with non-diabetic control sera). Other reports have described stimulation of insulin release from mouse islets by normal human serum (Idahl et al. 1980) or inhibition of glucose-stimulated secretion of insulin from mouse islet cells incubated in the presence of heat-inactivated IDDM patient sera for 2 h and subsequently in the presence of guinea pig serum as a source of complement (Boitard et al. 1981 , Sensi et al. 1985 . However, we have demonstrated that rat islet cells incubated in the presence of 10% IDDM patient serum undergo morphological changes resulting in increased buoyant cell density (apoptosis-associated cell shrinkage) after 4 h (Caraher et al. 1999) , which may result in an inhibition of insulin secretion via a mechanism closely linked with the signal transduction pathways responsible for cell death.
We report here that amino-acid-stimulated secretion of insulin was inhibited by prior culture of clonal BRIN-BD11 cells in the presence of 10% sera from newly diagnosed patients with IDDM, compared with that in normal human control sera (3·809 0·452 compared with 7·894 0·395 ng/20 min per 10 6 cells respectively, n=9; P<0·001). Cell viability was not altered by any of the incubation conditions described in this paper. The present study has also demonstrated that complement activation plays an important contributory role in the process of inhibition. Thus culture in IDDM sera depleted of components essential to the activation of the classical complement pathway (C1q) or alternative pathway (C3) resulted in significant reversal of the inhibition of insulin secretion observed in cells exposed to untreated IDDM sera (for seven of nine patients assessed in this study). In fact, removal of complement components C1q and C3 from IDDM sera returned alanine-stimulated insulin secretion to approximately the same level as that observed in -cells exposed to normal human sera or heat-inactivated IDDM sera.
Complement activation (assessed by SC5b-9 concentrations) occurred in medium supplemented with IDDM sera and normal human sera, to which BRIN-BD11 cells were exposed. However, supplementation of culture medium with serum from some, but not all, IDDM patients resulted in substantially greater concentrations of the TCCs compared with culture media supplemented with normal human sera. SC5b-9 concentrations were not significantly different in the culture medium of kidney epithelial cells incubated in the presence of 10% (v/v) IDDM sera or 10% (v/v) normal human sera, and were substantially less than in media supplemented with IDDM sera, to which an equivalent number of BRIN-BD11 cells were exposed.
Anti-GAD antibodies, ICA, and IAA were increased in six, five and three of the nine patient sera samples, respectively. The sera from two patients were positive for all three autoantibodies, and sera from four patients were positive for two of the three autoantibodies; sera from three patients assessed in this study were negative for all three of the autoantibodies. Interestingly, the rate of secretion of insulin from BD11 cells cultured in the presence of the sera from the last three patients was relatively high (approximately 5 ng/20 min per 10 6 cells) and, in one, was not significantly increased after depletion of the serum complement components, C1q and C3. Thus we suggest, that in the presence of increased concentrations of certain anti--cell autoantibodies (perhaps different antibodies in different patients), complement is activated at a faster rate in cell culture medium containing sera from diabetic patients, on exposure to autoantigen(s) present in the -cell line, BRIN-BD11. Complement activation then precipitates a failure in fuel metabolism, signal transduction, or insulin exocytosis. Although significant increases in soluble TCC (SC5b-9) were not achieved after incubation of the cells in the presence of the -cell line for all the patient sera samples used in our study, the amount of cell-associated TCC may well have increased significantly; we did not determine the amount of TCC attached to BD11 cell membranes in this study. Although complement activation contributed to the mechanism of inhibition of insulin secretion, complete reversal to the secretion rates observed for clonal -cells cultured in normal human sera or FCS was not quite achieved. This may indicate that other factors in IDDM sera contribute to the observed inhibition of insulin secretion. These factors are probably cytokines, as others have shown that interleukin (IL)-1 , alone (Zawalich & Diaz 1986 , Comens et al. 1987 , Sandler et al. 1987 or in combination with tumour necrosis factor- (Southern et al. 1990 , Dunger et al. 1996 cause substantial inhibition of insulin secretion from rat islets. It has also been reported that the cytokine, interferon-, can prime -cells for subsequent dysfunctional signals delivered by IL-1 (Heitmeier et al. 1997) .
The complement-stimulated pathway responsible for inhibition of insulin secretion is, as yet, unknown. Cytokine-induced DNA damage can be caused indirectly via upregulation of oxidant-moleculegenerating enzymes, such as inducible nitric oxide synthase (Dunger et al. 1996) or via activation of pre-existing endonucleases. As an increase in intracellular Ca 2+ occurs after complement attack (Newsholme et al. 1993 , and Ca 2+ -sensitive endonucleases exist in the nucleus, the latter pathway may be more important in IDDM-sera-induced DNA damage of -cells. DNA fragmentation may interfere in the process of insulin secretion either directly, as the insulin gene may be disrupted, leading to inhibition of transcription and translation, or indirectly, as DNA repair is a process that is energy-requiring (and NAD + -requiring, because of the increased activity of the repair enzyme, poly (ADP-ribose) polymerase), thus diverting energy and cellular NAD + stores from that required for insulin storage and secretion to that required for repair.
We are aware of one study in which it was reported that autoantibodies directed against surface antigens inhibited the secretion of insulin from mouse islets via a mechanism that did not involve inhibition of -cell glucose metabolism (Dronfield et al. 1995) . The authors suggested that autoantibody-induced inhibition of insulin secretion must involve inhibition of processes downstream of glucose oxidation.
A number of previous studies have attempted to demonstrate complement mediated -cell cytotoxicity after exposure to IDDM patient sera. These sera were found to be cytotoxic to rat islet cells (Doberson et al. 1980) , hamster islet cells (Rittenhouse et al. 1980) or clonal rat islet cells (Eisenbarth et al. 1981) , compared with non-IDDM (Type II diabetic) or non-diabetic sera. In addition, one report has detailed that normal human sera (heat inactivated) can exhibit levels of cytotoxicity similar to those of newly diagnosed IDDM sera in the presence of rabbit sera (Cavender et al. 1986 ). The problems associated with heterologous activation of complement may have contributed to these findings by Cavender et al. (1986) . However, more recently Radillo et al. (1996) have reported that the cytotoxic activity of IDDM sera towards human pancreatic islets is dependent upon TCC formation and deposition on insulin containing cells. We have demonstrated here that, in a 10% concentration, IDDM sera is not cytotoxic to the rat clonal BRIN-BD11 -cell line; however, alanine-stimulated secretion of insulin was clearly inhibited by exposure of these cells to IDDM sera for 24 h before acute tests of insulin secretion.
In conclusion, the present study suggests that, in vivo, complement activation in the pancreatic islets of Langerhans may contribute to -cell dysfunction and the development of hyperglycaemia. This hypothesis would fit with the known slow pathogenesis of most types of IDDM, from detection of immune system activation to clinical diagnosis. Evidence that humoral factors may play a part in the induction of -cell dysfunction and death in vivo has been provided by O'Brien et al. (1997) , who have described detectable levels of -cell apoptosis occurring before lymphocytic infiltration of islets in the nonobese diabetic/Lt mouse.
